SANTA MONICA, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) — Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reports that the company mistakenly reissued the press release this afternoon entitled, “Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).” This press release is a duplicate of the press release issued on December 20, 2021. The company regrets the error.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…
DUBLIN--(BUSINESS WIRE)--The "Global Medical Device Connectivity Market: Analysis By Product & Services, By Technology, By…
VANCOUVER, WA / ACCESSWIRE / March 22, 2024 / At just eight years old, Zeke…
GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB…
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or…
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…